Biomarkers for Alzheimer’s Disease Drug Development -

Biomarkers for Alzheimer’s Disease Drug Development

Robert Perneczky (Herausgeber)

Buch | Hardcover
347 Seiten
2024 | 2nd ed. 2024
Springer-Verlag New York Inc.
978-1-0716-3773-9 (ISBN)
181,89 inkl. MwSt
This fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic. 
Authoritative and practical, Biomarkers for Alzheimer’s Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease.

Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis in Real-World Settings.- Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approaches.- CSF N-Glycomics Using High Throughput UPLC-ESI Techniques in Alzheimer’s Disease.- CSF N-Glycomics Using MALDI MS Techniques.- Optimized Pre-Analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Disease.- Mass Spectrometry-Based Metabolomics Multi-Platform for Alzheimer’s Disease Research.- Analysis of Resting-State Functional Magnetic Resonance Imaging in Alzheimer's Disease.- Diffusion Tensor Imaging in Alzheimer’s Studies.- Magnetic Resonance Spectroscopy (MRS) in Alzheimer’s Disease.- Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies.- Amyloid PET Imaging: Standard Procedures and Semiquantification.- PET Imaging to Measure Neuroinflammation In Vivo.- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.- High-Throughput Lipidomics and Metabolomics Profiling for Brain Tissue and Biofluid Samples in Neurodegenerative Disorders.- Neuropathological Assessment as an Endpoint in Clinical Trial Design.- Non-Invasive Visualization of Amyloid-Beta Deposits in Alzheimer’s Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent.- Brain Banking in Dementia Studies.- Speech-Based Digital Biomarkers for Alzheimer’s Research.- cCOG Web-Based Cognitive Assessment Tool.- In Silico Models to Validate Novel Blood-Based Biomarkers.

Erscheinungsdatum
Reihe/Serie Methods in Molecular Biology
Zusatzinfo 49 Illustrations, color; 2 Illustrations, black and white; XII, 347 p. 51 illus., 49 illus. in color.
Verlagsort New York, NY
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Geriatrie
Medizin / Pharmazie Studium
Naturwissenschaften Biologie Humanbiologie
Naturwissenschaften Biologie Zoologie
Schlagworte Amyloid-targeting antibody • Digital biomarkers • Drug targets • Neurodegenerative disorder • Neuroimaging analysis • preclinical and clinical research
ISBN-10 1-0716-3773-8 / 1071637738
ISBN-13 978-1-0716-3773-9 / 9781071637739
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Das Wichtigste für Ärztinnen und Ärzte aller Fachrichtungen

von Klaus Hager; Olaf Krause

Buch | Softcover (2021)
Urban & Fischer in Elsevier (Verlag)
37,00

von Gisela Mötzing; Susanna Schwarz

Buch | Softcover (2022)
Urban & Fischer in Elsevier (Verlag)
33,00
Zukunftssicherheit der Geriatrie - Konzept und Bedarfszahlen

von Bundesverband Geriatrie e.V.

Buch | Softcover (2023)
Kohlhammer (Verlag)
36,00